Our analyses indicate anti-ZSCAN1 autoantibodies as a marker for early diagnosis that may also be useful in evaluating disease severity and the need for immunosuppressive treatment in patients with ROHHAD syndrome not associated with a tumor. Here, ZSCAN1 is linked to neoplasm.